Skip to main content

Pharmacological randomized controlled trials in acute respiratory distress syndrome mortality

Introduction

Acute lung injury and acute respiratory distress syndrome are common conditions encountered in the ICU. Whether mortality has decreased over time or not, they are still many unanswered questions about the impact of pharmacological treatment on ALI/ARDS mortality.

Methods

The objectives were to perform a review of the literature in search of the randomized control trials that asses the pharmacological impact in ALI/ARDS on all-cause mortality. We included all RCTs of pharmacological treatments in ALI/ARDS that had an impact in mortality in adults. We excluded RCTs that included patients <18 years old and animals. We also excluded trials that tested fluid therapy, mechanical ventilation, nonpharmacological treatments, antibiotics and reviews. No date or language restriction was applied.

Results

We included 37 RCTs involving 6,303 patients in different ALI/ARDS treatment modalities: steroids (n = 271), enteral nutrition (n = 411), surfactant (n = 1,754), nitric oxide (n = 1,342), APC (n = 75), muscle relaxants (n = 340), prostaglandins (n = 550), NAC (n = 127), silvelastat (n = 492), rPAF-HD (n = 127) lisofylline (n = 235), rFVIIa antagonist (n = 214), OTZ (n = 215) and verapamile-procaine compound (n = 150).

Conclusions

Only steroid treatment (methylprednisolone) and nutritional therapy (EPA + GLA + antioxidants) showed a trend towards reduced mortality. Other treatments were associated with reduced morbidity. However, many empirical treatments are still used in day-to-day practice.

References

  1. 1.

    Brun-Buisson C, Lemaire F, et al.: Intensive Care Med. 2004, 30: 51-61.

    Article  PubMed  Google Scholar 

  2. 2.

    Phua J, Ferguson ND, et al.: Am J Respir Crit Care Med. 2010, in press.

    Google Scholar 

  3. 3.

    Tang , et al.: Crit Care Med. 2009, 37: 1594-1603.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Adhikari NKJ, Burns KEA, Meade MO, Ratnapalan M: Cochrane Database Syst Rev. 10: CD004477.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to C Santacruz.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Santacruz, C., Carrasco, E. & Dantas do Amaral, J.W. Pharmacological randomized controlled trials in acute respiratory distress syndrome mortality. Crit Care 15, P189 (2011). https://doi.org/10.1186/cc9609

Download citation

Keywords

  • Nitric Oxide
  • Prostaglandin
  • Lung Injury
  • Pharmacological Treatment
  • Methylprednisolone